| 书目名称 | Pancreatic Cancer | | 副标题 | Current Therapeutics | | 编辑 | Shubham Pant | | 视频video | | | 概述 | Illuminates therapeutic advances in pancreatic cancer.Explains the incorporation of Next generation and germline sequencing in the care of patients.Provides the latest therapies that target tumor stro | | 图书封面 |  | | 描述 | . .Pancreatic cancer is a challenging and complex disease characterized by a dense fibrotic stroma and an immunosuppressive tumor microenvironment. Until recently, there were no predictive biomarkers to personalize selection of targeted or biologic therapies as a part of standard of care treatment. Moreover, the regulatory immune population of cells creates a “cold”, non-immunogenic tumor that is resistant to immunotherapies including checkpoint inhibitors. However, in the last few years, there has been substantial progress in our understanding of the role mutations in the pathogenesis of disease leading to increased adoption of germline and next generation sequencing to identify mutations and fusions to optimize selection of therapies and select patients for clinical trials of targeted agents..This book provides a comprehensive, global overview on therapy for pancreatic cancer, exploring approved therapies and focusing on the “Next” in drug development including molecularly targeted therapy and efforts at “Drugging the Undruggable”: the KRAS mutation. It also addresses efforts at targeting the inhospitable stroma to improve drug delivery to the tumor cells, incorporating ct DNA ( | | 出版日期 | Book 2023 | | 关键词 | Resection; Metastasis; immunotherapy; targeted therapy; adjuvant treatment; neoadjuvant treatment; microbi | | 版次 | 1 | | doi | https://doi.org/10.1007/978-3-031-38623-7 | | isbn_softcover | 978-3-031-38625-1 | | isbn_ebook | 978-3-031-38623-7 | | copyright | The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerl |
The information of publication is updating
|
|
发表于 2025-3-21 16:52:34
